BioTuesdays
Feature

XTL hopes to begin major lupus trial next year

By Len Zehr XTL Biopharmaceuticals (NASDAQ:XTLB; TASE:XTL) is aiming to begin a Phase 2b clinical trial in the first half of 2015 with its hCDR1 peptide to treat patients with systemic lupus erythematosus (SLE). “We are...

July 22, 2014
Feature

Medifocus readies marketing expansion of Prolieve

By Len Zehr Medifocus (OTCQX:MDFZF; TSX-V:MFS) is raising $6-million to $10-million to expand the sales and marketing of its minimally invasive Prolieve device as a treatment for benign prostatic hyperplasia (BPH), or...

July 8, 2014
Feature

Response Biomedical charting turnaround story

By Len Zehr The new management team of Response Biomedical (OTCBB:RPBIF; TSX:RBM), with the strong support of its controlling shareholder, OrbiMed Advisors, has adopted an aggressive plan to drive sales and achieve...

July 1, 2014
Feature

Enrollment in Athersys stroke trial nears completion

By Len Zehr Athersys (NASDAQ:ATHX) expects to complete enrollment by the end of the summer in a Phase 2 clinical trial of its MultiStem cell therapy in about 140 moderate to moderately-severe ischemic stroke patients...

May 27, 2014
Feature

Knight won’t rest til it bests Paladin

By Len Zehr “It is entirely the goal of Knight Therapeutics (TSX:GUD) to duplicate the success of Paladin Labs,” says president and CEO, Jonathan Ross Goodman, who turned Paladin into a premier distributor of specialty...

May 13, 2014
Feature

In conversation with Alistair Duncan

By Len Zehr As a co-founder, president and CEO of closely held viDA Therapeutics, a tissue repair company, Alistair Duncan has developed an affinity for doing biotech startups. From 1998 to 2008, he was president and...

May 6, 2014
Feature

Transition moves into late-stage drug development

By Len Zehr Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) has added late-stage drug development to its operations with its acquisition from Perrigo plc (NYSE, TASE:PRGO) of neuropsychiatric drug candidate, ELND005...

March 18, 2014
Feature

Alpha Cancer to test oncology game changer

By Len Zehr Closely held Alpha Cancer Technologies, which is going public in a reverse takeover of Bradmer Pharmaceuticals (TSX-V:BMR-H), plans to begin testing patients with ovarian cancer this year with its drug...

March 11, 2014
Feature

Gamida Cell shifts focus to NiCord stem cell product

By Len Zehr Closely held Gamida Cell has shifted its focus to its second-generation stem cell product, NiCord, for the treatment of hematological malignancies and non-malignant hematological diseases in the wake of an...

March 4, 2014
Feature

Advaxis readies cervical cancer pivotal trial

By Len Zehr Advaxis (NASDAQ:ADXS) hopes to begin a registration trial before the end of the year with its next-generation immunotherapy, ADXS-HPV, for the treatment of invasive cervical cancer. “We are pleased with the...

February 25, 2014
Feature

In conversation with Michael Vidne

By Len Zehr As director of business development for closely held NovellusDx, Michael Vidne has an enviable position in one of the hottest areas of health care: personalized medicine. A former consultant in the West...

February 11, 2014
Feature

Venaxis pivotal APPY1 data due in March

By Len Zehr Venaxis (NASDAQ:APPY) expects to report top-line data in March from a pivotal study of its rapid, protein biomarker-based assay for appendicitis, the APPY1 Test and, depending on the results, submit a final...

February 4, 2014
Feature

In conversation with Elias Vamvakas

By Len Zehr As CEO of San Diego-based TearLab (NASDAQ:TEAR; TSX:TLB), eye care entrepreneur, Elias Vamvakas, has scored another home run with a medical device for the diagnosis and management of dry eye disease (DED)...

January 28, 2014
Feature

Encision to launch simplified AEM device

By Len Zehr The new management team at Encision (OTC:ECIA) plans to launch in late spring a simplified version of its Active Electrode Monitoring (AEM) technology, known as the EndoShield Burn Protection System, to...

January 21, 2014